Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals

Author:

Dai Yu-Ching1,Lin Yen-Chia1,Ching Lauren L.12,Tsai Jih-Jin345,Ishikawa Kyle6,Tsai Wen-Yang12,Chen John J.6,Nerurkar Vivek R.12,Wang Wei-Kung12ORCID

Affiliation:

1. Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

2. Pacific Center for Emerging Infectious Diseases, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

3. Tropical Medicine Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

4. Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

5. School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

6. Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA

Abstract

Despite improved understanding of the biology of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the evolutionary trajectory of the virus is uncertain, and the concern of future antigenically distinct variants remains. Current recommendations for a COVID-19 vaccine booster dose are primarily based on neutralization capacity, effectiveness against circulating variants of concern (VOC), and other host factors.

Funder

City and County of Honolulu

CU | National Cancer Institute, Cairo University

Hawaii Community Foundation

MOHW | Health Promotion Administration, Ministry of Health and Welfare

National Health Research Institutes

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Reference64 articles.

1. Johns Hopkins University Coronavirus Research Center. COVID-19 dashboard. Johns Hopkins University Baltimore MD. https://coronavirus.jhu.edu/map.html. Accessed 8 June 2022.

2. WHO. 2022. Tracking SARS-CoV-2 variants. Updated June 6 2022. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. WHO Geneva Switzerland.

3. SARS-CoV-2 variants, spike mutations and immune escape

4. CDC. 2023. The possibility of COVID-19 after vaccination: breakthrough infections. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html. CDC Atlanta GA.

5. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Immunological Insights: A Multicenter Longitudinal Study on Humoral Response to COVID-19 Vaccines in Greece;Acta Microbiologica Hellenica;2024-06-05

2. COVID-19 vaccines and beyond;Cellular & Molecular Immunology;2024-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3